{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:24:08Z","timestamp":1793391848975,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Ministry of Food and Drug Safety","doi-asserted-by":"publisher","award":["RS-2024-00331833"],"award-info":[{"award-number":["RS-2024-00331833"]}],"id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002631","name":"Gachon University","doi-asserted-by":"publisher","award":["GCU-202209160001"],"award-info":[{"award-number":["GCU-202209160001"]}],"id":[{"id":"10.13039\/501100002631","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clim.2024.110424","type":"journal-article","created":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T19:43:13Z","timestamp":1735328593000},"page":"110424","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Clinical advancements in mRNA vaccines against viral infections"],"prefix":"10.1016","volume":"271","author":[{"given":"Munazza","family":"Fatima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil-Gu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kee-Jong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2024.110424_bb0005","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.clim.2024.110424_bb0010","doi-asserted-by":"crossref","first-page":"7057","DOI":"10.1093\/nar\/12.18.7057","article-title":"Functional messenger RNAs are produced by SP6 in vitro transcription of cloned cDNAs","volume":"12","author":"Krieg","year":"1984","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.clim.2024.110424_bb0015","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.4049\/jimmunol.165.10.5713","article-title":"Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA","volume":"165","author":"Koido","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2024.110424_bb0020","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/4031","article-title":"In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model","volume":"4","author":"Mandl","year":"1998","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0025","first-page":"262","article-title":"Gene gun delivery of mRNA in situ results in efficient transgene expression and genetic immunization","volume":"3","author":"Qiu","year":"1996","journal-title":"Gene Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics--developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2024.110424_bb0035","first-page":"11","article-title":"Principles of translational control","author":"Hershey","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.clim.2024.110424_bb0040","first-page":"11","article-title":"Protein synthesis and translational control: a historical perspective","author":"Tahmasebi","year":"2019","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.clim.2024.110424_bb0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.tibtech.2004.08.012","article-title":"High-throughput cell-free systems for synthesis of functionally active proteins","volume":"22","author":"Spirin","year":"2004","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.clim.2024.110424_bb0050","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0006-291X(69)90720-7","article-title":"The synthesis of mouse hemoglobin \u03b2-chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA","volume":"37","author":"Raymond","year":"1969","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.clim.2024.110424_bb0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/274923a0","article-title":"Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes","volume":"274","author":"Dimitriadis","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.clim.2024.110424_bb0060","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.clim.2024.110424_bb0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clim.2024.110424_bb0070","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.clim.2024.110424_bb0075","first-page":"1397","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2024.110424_bb0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Kariko","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2024.110424_bb0085","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0090","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2024.110424_bb0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/nbt.2436","article-title":"Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection","volume":"30","author":"Petsch","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2024.110424_bb0100","doi-asserted-by":"crossref","first-page":"14604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.clim.2024.110424_bb0105","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1016\/j.vaccine.2019.04.074","article-title":"mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials","volume":"37","author":"Feldman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2024.110424_bb0110","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","article-title":"Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial","volume":"390","author":"Alberer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2024.110424_bb0115","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0120","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0125","article-title":"Safety and immunogenicity of an mRNA-based human Metapneumovirus and parainfluenza virus type 3 combined vaccine in healthy adults. Open forum","volume":"9","author":"August","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0130","series-title":"Moderna Announces Positive Phase 1\/2 Data from mRNA-1083, the Company's Combination Vaccine Against Influenza and COVID-19 2023 October:1\u20134","author":"Moderna","year":"2023"},{"key":"10.1016\/j.clim.2024.110424_bb0135","first-page":"9","article-title":"Advancements in mRNA encoded antibodies for passive immunotherapy","author":"Deal","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.clim.2024.110424_bb0140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.clim.2024.110424_bb0145","first-page":"10","article-title":"A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs","volume":"2","author":"Kallen","year":"2014","journal-title":"Ther. Adv. Vacc."},{"key":"10.1016\/j.clim.2024.110424_bb0150","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/s41467-018-05482-0","article-title":"Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies","volume":"9","author":"Pardi","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2024.110424_bb0155","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-017-0032-6","article-title":"Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines","volume":"2","author":"Lutz","year":"2017","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.clim.2024.110424_bb0160","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0165","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.clim.2024.110424_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.clim.2024.110424_bb0175","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12195-018-0536-9","article-title":"Lipid polymer hybrid nanomaterials for mRNA delivery","volume":"11","author":"Zhao","year":"2018","journal-title":"Cell. Mol. Bioeng."},{"key":"10.1016\/j.clim.2024.110424_bb0180","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticlesfrom liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.clim.2024.110424_bb0185","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.smim.2017.08.015","article-title":"Delivering the right message: challenges and opportunities in lipid nanoparticles-mediated modified mRNA therapeutics-an innate immune system standpoint","volume":"34","author":"Granot","year":"2017","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.clim.2024.110424_bb0190","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","article-title":"Delivering the messenger: advances in Technologies for Therapeutic mRNA delivery","volume":"27","author":"Kowalski","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0195","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2024.110424_bb0200","first-page":"709","article-title":"mRNA-based therapeutics - advances and perspectives","volume":"81","author":"Sergeeva","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.clim.2024.110424_bb0205","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/d41586-021-02483-w","article-title":"The tangled history oF mRNA vaccines","volume":"597","author":"Dolgin","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clim.2024.110424_bb0210","series-title":"COVID-19 - Landscape of Novel Coronavirus Candidate Vaccine Development Worldwide","author":"WHO","year":"2023"},{"key":"10.1016\/j.clim.2024.110424_bb0215","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA vaccine against SARS-CoV-2 - preliminary report","volume":"383","author":"Jackson","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0225","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1056\/NEJMoa2109522","article-title":"Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents","volume":"385","author":"Ali","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0230","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0235","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0240","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0245","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0250","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1126\/science.372.6549.1381","article-title":"What went wrong with CureVac's mRNA vaccine?","volume":"372","author":"Cohen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.clim.2024.110424_bb0255","doi-asserted-by":"crossref","unstructured":"Salmanton-Garcia J, Neuhann JM, Stemler J, Carcas A, Fr\u00edas-Iniesta J, Bethe U, et al. 2383. Immunogenicity and reactogenicity of a first booster with BNT162b2 or full-dose mRNA-1273: a randomised trial in adults \u226575 years (EU-COVAT-1) from the VACCELERATE consortium. Open Forum Infect. Dis. 2023;10:ofad500.2003.","DOI":"10.1093\/ofid\/ofad500.2003"},{"key":"10.1016\/j.clim.2024.110424_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.07.014","article-title":"Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged \u2265 65 years in the United States","volume":"42","author":"Kirk","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2024.110424_bb0265","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s40121-024-00936-z","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines among older adults: systematic literature review and Meta-analysis using the GRADE framework","volume":"13","author":"Kavikondala","year":"2024","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0270","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1016\/j.vaccine.2024.04.096","article-title":"mRNA COVID-19 vaccine safety among older adults from the Canadian National Vaccine Safety Network","volume":"42","author":"Soe","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2024.110424_bb0275","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.cell.2021.03.013","article-title":"Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity","volume":"184","author":"Garcia-Beltran","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.clim.2024.110424_bb0280","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1002\/jmv.27588","article-title":"Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines","volume":"94","author":"Araf","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.clim.2024.110424_bb0285","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the omicron (B.1.1.529) variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/spectrum.02252-21","article-title":"Vaccine-induced antibody responses against SARS-CoV-2 variants-of-concern six months after the BNT162b2 COVID-19 mRNA vaccination","volume":"10","author":"Jalkanen","year":"2022","journal-title":"Microbiol. Spectr."},{"key":"10.1016\/j.clim.2024.110424_bb0295","first-page":"26","article-title":"BNT162b2 and mRNA-1273 vaccine effectiveness against SARS-CoV-2 and variants in the urban underserved population","author":"Weng","year":"2023","journal-title":"R. I. Med. J."},{"key":"10.1016\/j.clim.2024.110424_bb0300","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0305","first-page":"1","article-title":"Booster dose of self-amplifying SARS-CoV-2 RNA vaccine vs. mRNA vaccine: a phase 3 comparison of ARCT-154 with Comirnaty","author":"Oda","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.clim.2024.110424_bb0310","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1056\/NEJMoa2213082","article-title":"Bivalent omicron BA.1-adapted BNT162b2 booster in adults older than 55 years","volume":"388","author":"Winokur","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0315","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0320","article-title":"Effectiveness of BA.1- and BA.4\/BA. 5-containing bivalent COVID-19 mRNA vaccines against symptomatic SARS-CoV-2 infection during the BA.5-dominant period in Japan. Open forum","volume":"10","author":"Arashiro","year":"2023","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0325","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S1473-3099(23)00122-6","article-title":"Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study","volume":"23","author":"Arbel","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0330","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ijid.2023.08.010","article-title":"Comparing the effectiveness of bivalent and monovalent COVID-19 vaccines against COVID-19 infection during the winter season of 2022-2023: a real-world retrospective observational matched cohort study in the Republic of Korea","volume":"135","author":"Chae","year":"2023","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0335","article-title":"Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged >\/=50 years in Nordic countries: nationwide cohort study","volume":"382","author":"Andersson","year":"2023","journal-title":"BMJ"},{"key":"10.1016\/j.clim.2024.110424_bb0340","series-title":"Coronavirus (COVID-19) Update: FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines","author":"U.S. FDA","year":"2023"},{"key":"10.1016\/j.clim.2024.110424_bb0345","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.clim.2024.110424_bb0350","first-page":"1","article-title":"Safety and immunogenicity of XBB.1.5-containing mRNA vaccines","author":"Chalkias","year":"2023","journal-title":"medRxiv"},{"key":"10.1016\/j.clim.2024.110424_bb0355","series-title":"FDA Takes Action on Updated mRNA COVID-19 Vaccines to Better Protect Against Currently Circulating Variants","author":"U.S. FDA","year":"2023"},{"key":"10.1016\/j.clim.2024.110424_bb0360","author":"CDC"},{"key":"10.1016\/j.clim.2024.110424_bb0365","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2190690","article-title":"Interim analysis of a phase 1 randomized clinical trial on the safety and immunogenicity of the mRNA-1283 SARS-CoV-2 vaccine in adults","volume":"19","author":"Yassini","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.clim.2024.110424_bb0370","series-title":"Moderna Achieves Positive Interim Results From Phase 3 Trial of Next-Generation COVID-19 Vaccine","author":"Moderna","year":"2024"},{"key":"10.1016\/j.clim.2024.110424_bb0375","series-title":"RNA Vaccines: Methods and Protocols","first-page":"167","article-title":"Production and evaluation of nucleoside-modified mRNA vaccines for infectious diseases","author":"Vadovics","year":"2024"},{"key":"10.1016\/j.clim.2024.110424_bb0380","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/0113816128296588240321072042","article-title":"Innovative strategies to enhance mRNA vaccine delivery and effectiveness: mechanisms and future outlook","volume":"30","author":"Abhishek","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.clim.2024.110424_bb0385","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.3390\/v15081760","article-title":"Vaccines\u2019 new era-RNA vaccine","volume":"15","author":"Zhou","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.clim.2024.110424_bb0390","doi-asserted-by":"crossref","first-page":"080","DOI":"10.69613\/vpxx7e92","article-title":"The transformative potential of mRNA vaccines in revolutionizing vaccine development and therapeutic applications: review article","volume":"2","author":"Vidhyalakshmi","year":"2024","journal-title":"J. Pharm. Insights Res."},{"key":"10.1016\/j.clim.2024.110424_bb0395","first-page":"3966","article-title":"mRNA vaccines for infectious diseases: research progress and applications","volume":"39","author":"Qin","year":"2023","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"key":"10.1016\/j.clim.2024.110424_bb0400","first-page":"1","article-title":"Safety and immunogenicity of mRNA-1010, an investigational seasonal influenza vaccine, in healthy adults: final results from a phase 1\/2 randomized trial","author":"Ananworanich","year":"2024","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0405","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1473-3099(24)00493-6","article-title":"Safety and immunogenicity of mRNA-based seasonal influenza vaccines formulated to include multiple a\/H3N2 strains with or without the B\/Yamagata strain in US adults aged 50\u201375 years: a phase 1\/2, open-label, randomised trial","volume":"25","author":"Hsu","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.1473","article-title":"1639. A review of clinical safety, Reactogenicity, and immunogenicity of an mRNA-based seasonal influenza vaccine (mRNA-1010) in adults","volume":"10","author":"Soens","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0415","series-title":"Moderna Expands the Field of mRNA Medicine with Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease","author":"Moderna","year":"2023"},{"key":"10.1016\/j.clim.2024.110424_bb0420","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.clim.2024.110424_bb0425","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","article-title":"A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults","volume":"17","author":"Aliprantis","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.clim.2024.110424_bb0430","series-title":"Pipeline Progress, Business Updates, and First Quarter 2019 Financial Results","author":"Moderna","year":"2019"},{"key":"10.1016\/j.clim.2024.110424_bb0435","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ofid\/ofac492.312","article-title":"234. Safety and immunogenicity of mRNA-1345, an mRNA-based RSV vaccine in younger and older adult cohorts: results from a phase 1, randomized clinical trial","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0440","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1056\/NEJMoa2307079","article-title":"Efficacy and safety of an mRNA-based RSV PreF vaccine in older adults","volume":"389","author":"Wilson","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0445","author":"Moderna"},{"key":"10.1016\/j.clim.2024.110424_bb0450","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/j.jval.2024.03.473","article-title":"EE174 assessing the cost-effectiveness of an mRNA-based Rsv vaccine (mRNA-1345) amongst Canadian adults aged \u226560 years","volume":"27","author":"Fust","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.clim.2024.110424_bb0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj7843","article-title":"Fatal enhanced respiratory syncytial virus disease in toddlers","volume":"13","author":"Polack","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0460","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.anai.2020.03.017","article-title":"The journey to a respiratory syncytial virus vaccine","volume":"125","author":"Mejias","year":"2020","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.clim.2024.110424_bb0465","series-title":"Moderna Announces First Participant Dosed in Phase 1 Study of Its HIV Trimer mRNA Vaccine","author":"Moderna","year":"2022"},{"key":"10.1016\/j.clim.2024.110424_bb0470","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.immuni.2016.08.016","article-title":"HIV vaccine design to target germline precursors of glycan-dependent broadly neutralizing antibodies","volume":"45","author":"Steichen","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.clim.2024.110424_bb0475","first-page":"9","article-title":"HIV mRNA vaccines-Progress and future paths","author":"Mu","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.clim.2024.110424_bb0480","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ofid\/ofad500.2475","article-title":"2892. Safety and immunogenicity of mRNA-1647, an mRNA-based cytomegalovirus vaccine in healthy adults: results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial","volume":"10","author":"Panther","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0485","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","article-title":"The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials","volume":"23","author":"Essink","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.clim.2024.110424_bb0490","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.vaccine.2020.12.070","article-title":"Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: a phase 1 trial","volume":"39","author":"Aldrich","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.clim.2024.110424_bb0495","first-page":"31","article-title":"Self-amplifying mRNA-based vaccine technology and its mode of action","volume":"440","author":"Maruggi","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.clim.2024.110424_bb0500","first-page":"12","article-title":"Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.clim.2024.110424_bb0505","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1038\/s41467-022-31005-z","article-title":"Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection","volume":"13","author":"Rappaport","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2024.110424_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2024.114204","article-title":"Less is more: self-amplifying mRNA becomes self-killing upon dose escalation in immune-competent retinal cells","volume":"196","author":"Vanluchene","year":"2024","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.clim.2024.110424_bb0515","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01858-21","article-title":"The nonmonotonic dose dependence of protein expression in cells transfected with self-amplifying RNA","volume":"96","author":"Tanimoto","year":"2022","journal-title":"J. Virol."},{"key":"10.1016\/j.clim.2024.110424_bb0520","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2024.110424_bb0525","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.clim.2024.110424_bb0530","article-title":"Editorial: COVID-19 booster vaccination: increasing immunity against life-threatening infection","volume":"11","author":"Yorsaeng","year":"2023","journal-title":"Front. Public Health"},{"key":"10.1016\/j.clim.2024.110424_bb0535","article-title":"COVID-19 Vaccines\u2019 protection over time and the need for booster doses; a systematic review","volume":"10","author":"Dadras","year":"2022","journal-title":"Arch. Acad. Emerg. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0540","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2399382","article-title":"Genomic insights into mRNA COVID-19 vaccines efficacy: linking genetic polymorphisms to waning immunity","volume":"20","author":"Hsieh","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.clim.2024.110424_bb0545","doi-asserted-by":"crossref","DOI":"10.3389\/falgy.2021.801322","article-title":"COVID-19 vaccine anaphylaxis: current evidence and future approaches","volume":"2","author":"Laisuan","year":"2021","journal-title":"Front. Allergy."},{"key":"10.1016\/j.clim.2024.110424_bb0550","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.clim.2024.110424_bb0555","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.18505","article-title":"Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and Interdose interval among adolescents and adults in Ontario, Canada","volume":"5","author":"Buchan","year":"2022","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.clim.2024.110424_bb0560","doi-asserted-by":"crossref","first-page":"513","DOI":"10.7326\/M21-4502","article-title":"Case series of thrombosis with thrombocytopenia syndrome after COVID-19 vaccination-United States, December 2020 to August 2021","volume":"175","author":"See","year":"2022","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.clim.2024.110424_bb0565","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/diseases12100231","article-title":"Cytokine storms and anaphylaxis following COVID-19 mRNA-LNP vaccination: mechanisms and therapeutic approaches","volume":"12","author":"Awaya","year":"2024","journal-title":"Diseases"},{"key":"10.1016\/j.clim.2024.110424_bb0570","first-page":"486","article-title":"A lipid nanoparticle platform incorporating trehalose glycolipid for exceptional mRNA vaccine safety","volume":"38","author":"Bae","year":"2024","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.clim.2024.110424_bb0575","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2024.2333123","article-title":"mRNA vaccine designs for optimal adjuvanticity and delivery","volume":"21","author":"Mochida","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.clim.2024.110424_bb0580","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068632","article-title":"Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis","volume":"376","author":"Lee","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.clim.2024.110424_bb0585","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1097\/CM9.0000000000002505","article-title":"Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients","volume":"135","author":"Song","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.clim.2024.110424_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121570","article-title":"An imidazole modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates","volume":"286","author":"Ripoll","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.clim.2024.110424_bb0595","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.01775-23","article-title":"Circular RNA vaccines with long-term lymph node-targeting delivery stability after lyophilization induce potent and persistent immune responses","volume":"15","author":"Wan","year":"2024","journal-title":"mBio"},{"key":"10.1016\/j.clim.2024.110424_bb0600","first-page":"9","article-title":"Dissolvable microneedle patches to enable increased access to vaccines against SARS-CoV-2 and future pandemic outbreaks","author":"O\u2019Shea","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.clim.2024.110424_bb0605","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41587-023-01774-z","article-title":"A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines","volume":"42","author":"Vander Straeten","year":"2023","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.clim.2024.110424_bb0610","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2023.2256422","article-title":"An mRNA-based broad-spectrum vaccine candidate confers cross-protection against heterosubtypic influenza a viruses","volume":"12","author":"Xiong","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.clim.2024.110424_bb0615","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s43856-022-00123-6","article-title":"Assessing the impact of novelty and conformity on hesitancy towards COVID-19 vaccines using mRNA technology","volume":"2","author":"Leong","year":"2022","journal-title":"Commun. Med."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624005333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661624005333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:03:28Z","timestamp":1778616208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661624005333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":123,"alternative-id":["S1521661624005333"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2024.110424","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical advancements in mRNA vaccines against viral infections","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2024.110424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110424"}}